Funding and Grants

Current Funding Opportunities

MCW Cancer Center Pilot Funding Program►OPEN NOW Highly Promising NCI R01 and New NCI R01 Submissions

 

 

 

MCW Cancer Center Pilot Funding Award Cycles

ONGOING RFA Highly Promising NCI R01 Resubmissions New NCI R01 Submissions
     

 

Spring 2017

Fall 2018

RFA Released

5/19/17

11/15/2017

LOI Due

6/2/2017

12/1/2017

Application Due

7/17/2017

1/15/2018

Review Committees

8/21 - 9/1/2017

2/15 – 2/26/2018

Funding Decision

First Thursday of October

First Thursday of April

Earliest Start Date

1/1/2018

6/1/2018

 

Now available, NCI grant development and submission support from the MCW Cancer Center. 

 

Now available, NCI grant development and submission support from the MCW Cancer Center. 

 

National Cancer Institute (NCI)

Open AllClose All
  Pediatric Early Phase Clinical Trials Network (UM1) (Deadline: LOI and Biosketch 7/31/17)

Pediatric Early Phase Clinical Trials Network (UM1)

The purpose of this Funding Opportunity Announcement (FOA) is to enhance NCI's program for conducting early phase clinical trials in children with cancer, currently supported as the Children's Oncology Group (COG) Phase 1 & Pilot Consortium. The overall goal is to ensure that high priority novel agents can be tested in pediatric patients in a timely manner. Towards this end, the clinical research activities now supported through the COG Phase 1 & Pilot Consortium will be continued (and enhanced) by the Pediatric Early Phase Clinical Trials Network (PEP-CTN).

*Limited Submission

Because this is a limited submission opportunity, nominees will be picked by a review panel of adult and pediatric cancer experts.

Deadline by noon on Friday, July 31:
Send your Letter of Intent (2-Page Maximum) and Biosketch to nmdavis@mcw.edu.

  • Applicants will be notified by August 7, 2017.
  • Deadline for Application to NCI: September 14, 2017
  HIV/AIDS and the Tumor Niche (R01) (Deadline: 8/5/17

HIV/AIDS and the Tumor Niche (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to advance our understanding of the role of the tumor niche or microenvironment in the risks, development, progression, diagnosis, and treatment of cancer observed in individuals with an underlying HIV infection or Acquired Immune Deficiency Syndrome (AIDS).

Applications due August 5, 2017

  Inter-organelle Communication in Cancer (R01) (Deadline: 8/16/17)

Inter-organelle Communication in Cancer (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects that examine how inter-organelle communication in cancer cells and/or tumor-associated cells affects cellular function, adaptation, and phenotypic plasticity.  

Applications due August 16, 2017

  Inter-organelle Communication in Cancer (R21) (Deadline: 8/16/17)

Inter-organelle Communication in Cancer (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects that examine how inter-organelle communication in cancer cells and/or tumor-associated cells affects cellular function, adaptation, and phenotypic plasticity.

Applications due August 16, 2017

  Global Pediatric Clinical Trials Network (U18) (Deadline: 8/22/17)

Global Pediatric Clinical Trials Network (U18)

The goals of this program are to support the development of the scientific infrastructure needed to plan and execute pediatric clinical trials through collaboration with stakeholders from academia, industry, parent/patient advocacy groups, and government agencies. The Global Pediatric Trial Network should be a coordinating resource for pediatric product development with sustainable global infrastructure to plan, start up, conduct, and close out pediatric clinical investigations.  There should be an emphasis on operational efficiency and network sustainability with early, systematic, and integrative approaches to pediatric studies.

Applications due August 22, 2017

  Cancer Prevention Fellowship Program (CPFP) (Deadline: 8/25/17)

Cancer Prevention Fellowship Program (CPFP)

The NCI Cancer Prevention Fellowship Program provides postdoctoral training opportunities in cancer prevention and control. Under the shared guidance of an individual NCI preceptor and the CPFP scientific staff, fellows will develop original research projects in cancer prevention and control. Collaboration with investigators throughout the NCI is encouraged. Research opportunities include, but are not limited to

  • biomarker development,
  • chemoprevention studies,
  • clinical cancer prevention research,
  • effectiveness and outcomes research,
  • epidemiology (clinical, environmental, genetic, molecular, nutritional),
  • ethics and evidence-based decision making (theoretical and practical studies),
  • health disparities and special populations,
  • laboratory-based research (chemoprevention, molecular biology and genetics, nutritional science),
  • screening and early detection,
  • social and behavioral research, and
  • statistical methodology (biometry and bioinformatics).

Preceptors who serve to guide and enrich each fellow's experience are selected from skilled investigators across all NCI divisions, participating FDA centers, or local academic institutions.

Applications due to NCI August 25, 2017

  Cancer Research Education Grants Program to Promote Diversity - Courses for Skills Development (R25) (Deadline: 9/25/17 or 1/25/18)

Cancer Research Education Grants Program to Promote Diversity - Courses for Skills Development (R25)

Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients, as well as the cause and reduction of cancer health disparities in accordance with the overall mission of the NCI

Applications due September 25, 2017 or January 25, 2018

  Advancing the Science of Geriatric Palliative Care (R01) (Deadline: 10/5/17)

Advancing the Science of Geriatric Palliative Care (R01)

This Funding Opportunity Announcement (FOA) encourages research grant applications focused on palliative care in geriatric populations. This FOA covers studies in a variety of settings including hospitals (and specific sites within hospitals including specialty medical or surgical wards, intensive care units, and emergency departments), post-acute care settings, outpatient clinics and doctors' offices, patients' homes and other residential settings, assisted living facilities, nursing homes, hospices, and other healthcare or community settings.

This FOA encourages both prospective studies and analyses of existing datasets, health and medical records, claims data, or other sources. Leveraging ongoing cohorts, intervention studies, networks, data and specimen repositories, and other existing research resources and infrastructure are encouraged. Study designs may include observational approaches, quasi-experimental designs, and interventional studies.

Applications due October 5, 2017

  Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01) (Deadline: 10/5/17)

Developing the Therapeutic Potential of the Endocannabinoid System for Pain Treatment (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support projects that will elucidate the therapeutic potential of the cannabinoids and endocannabinoid system in the development of mechanism-based therapies for pain.

Applications due October 5, 2017

  End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) With Serious Illnesses (R01) (Deadline: 10/5/17)

End-of-Life and Palliative Needs of Adolescents and Young Adults (AYA) With Serious Illnesses (R01)

The purpose of this funding opportunity announcement (FOA) is to foster research on the unique perspectives, needs, wishes, and decision-making processes of adolescents and young adults (AYA; defined by the World Health Organization and the Centers for Disease Control and Prevention as youth between 12 - 24 years of age) with serious, advanced illnesses; and research focused on specific end-of-life/palliative care (EOLPC) models that support the physical, psychological, spiritual, and social needs of AYA with serious illness, their families and caregivers.

Applications due October 5, 2017

  Ethical, Legal, and Social Implications (ELSI) of Genomics Research Project Grant Program (R01) (Deadline: 10/5/17)

Ethical, Legal, and Social Implications (ELSI) of Genomics Research Project Grant Program (R01)

This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. Applications may propose studies using either single or mixed methods. Proposed approaches may include but are not limited to data-generating qualitative and quantitative approaches, legal, economic and normative analyses, and other types of analytical and conceptual research methodologies, such as those involving the direct engagement of stakeholders.

*Limited Submission: Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept: - A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application. - A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application. - An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101). Please submit LOI by August 30th, 2017 so we can decipher if science is scientifically distinct.

Applications due October 5, 2017

  Gene Fusions in Pediatric Sarcomas (R01) (Deadline: 10/5/17)

Gene Fusions in Pediatric Sarcomas (R01)

The overall goal of this funding opportunity announcement (FOA) is to encourage the submission of research grant applications to investigate the molecular mechanisms by which oncogenic fusion genes and their gene products contribute to pediatric sarcoma initiation, progression, and metastasis. Better understanding of the molecular pathways activated by chromosomal translocations in pediatric sarcomas, and their relationship to oncogenesis and tumor progression, can elucidate mechanisms of cancer pathogenesis and potentially lead to novel therapeutics.

Applications due October 5, 2017

  High Throughput Screening (HTS) to Discover Chemical Probes (R01) (Deadline: 10/5/17)

High Throughput Screening (HTS) to Discover Chemical Probes (R01)

This Funding Opportunity Announcement (FOA) encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Through this FOA, NIH wishes to stimulate research in:

  1. Discovery and development of novel, small molecules for their potential use in studying disease treatments relevant to the missions of the participating NIH Institutes, and
  2. Discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease targets and processes.

Applications due October 5, 2017

  Integration of Individual Residential Histories into Cancer Research (R01) (Deadline: 10/5/17)

Integration of Individual Residential Histories into Cancer Research (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support substantive investigation of the role of individual residential histories in cancer etiology and outcomes, and to encourage the development of complex analytical strategies in support of substantive investigation.

Applications due October 5, 2017

  Nutrigenetics and Nutrigenomics Approaches for Nutrition Research (R01) (Deadline: 10/5/17)

Nutrigenetics and Nutrigenomics Approaches for Nutrition Research (R01)

The main objective of this Funding Opportunity Announcement (FOA) is to promote application of nutrigenetics and/or nutrigenomics approaches to nutrition research through collaborative interaction among nutrition researchers and experts in omics technologies.

Applications due October 5, 2017

  Population Health Interventions: Integrating Individual and Group Level Evidence (R01) (Deadline: 10/5/17)

Population Health Interventions: Integrating Individual and Group Level Evidence (R01)

To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes.

Applications due October 5, 2017

  US Tobacco Control Policies to Reduce Health Disparities (R01) (Deadline: 10/11/17)

US Tobacco Control Policies to Reduce Health Disparities (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies. Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups.

Application due October 11, 2017

  US Tobacco Control Policies to Reduce Health Disparities (R21) (Deadline: 10/11/17)

US Tobacco Control Policies to Reduce Health Disparities (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to support observational or intervention research focused on reducing health disparities in tobacco use in the United States. Specifically, this FOA is intended to stimulate scientific inquiry focused on innovative tobacco control policies. Applicants may propose projects in which the primary outcome of interest is on reducing tobacco use health disparities in vulnerable populations by utilizing tobacco prevention and control strategies. The long-term goal of this FOA is to reduce health disparities in health outcomes thereby reducing the excess disease burden of tobacco use within these groups.

Application due October 11, 2017

  Expanding Genome Integrity Assays to Population Studies (U01) (Deadline: 10/13/17)

Expanding Genome Integrity Assays to Population Studies (U01)

The funding opportunity announcement (FOA) will support development and pilot testing of assays, such as DNA repair capacity or mutation detection, that will facilitate the wider use of genome integrity investigation in epidemiological and population studies. Applications should aim to expand understanding of environmental diseases or exposure effects with the additional knowledge that genome integrity assays will bring. Transdisciplinary research should focus on a common research theme related to the role of environmental exposures.

NCI is interested in applications focused on DNA repair assays that relate to cancer risk and outcomes. As appropriate, the project should also facilitate integration of laboratory and human research to collectively increase understanding of the contribution of genome integrity variation and environmental factors to understand risk, pathogenesis, prevention, or resistance to disease.

Applications due October 13, 2017

  Ethical, Legal, and Social Implications (ELSI) of Genomics Small Research Grant Program (R03) (Deadline: 10/16/17)

Ethical, Legal, and Social Implications (ELSI) of Genomics Small Research Grant Program (R03)

This Funding Opportunity Announcement (FOA) invites Small Research Grant (R03) applications to study the ethical, legal and social implications (ELSI) of human genome research. These applications should be for small, self-contained research projects, such as those that involve single investigators. Of particular interest are projects that propose normative or conceptual analyses, including focused legal, economic, philosophical, anthropological, or historical analyses of new or emerging issues. This mechanism can also be used for the collection of preliminary data and the secondary analysis of existing data.

*Limited Submission: Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept: - A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application. - A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application. - An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101). Please submit LOI by August 30th, 2017 so we can decipher if science is scientifically distinct.

Applications due October 16, 2017

  Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R21) (Deadline: 10/16/17)

Ethical, Legal, and Social Implications (ELSI) of Genomics Exploratory/Developmental Research Grant Program (R21)

This Funding Opportunity Announcement (FOA) invites Exploratory/Developmental Research Grant (R21) applications that propose to study the ethical, legal and social implications (ELSI) of human genome research. These applications should propose single or mixed methods studies that break new ground, extend previous discoveries in new directions or develop preliminary data in preparation for larger studies. Of particular interest are studies that explore the implications of new or emerging genomic technologies or novel uses of genomic information.

*Limited Submission: Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept: - A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application. - A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application. - An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101). Please submit LOI by August 30th, 2017 so we can decipher if science is scientifically distinct.

Applications due October 16, 2017

  Integration of Individual Residential Histories into Cancer Research (R21) (Deadline: 10/16/17)

Integration of Individual Residential Histories into Cancer Research (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to support substantive investigation of the role of individual residential histories in cancer etiology and outcomes, and to encourage the development of complex analytical strategies in support of substantive investigation.

Applications due October 16, 2017

  Population Health Interventions: Integrating Individual and Group Level Evidence (R21) (Deadline: 10/16/17)

Population Health Interventions: Integrating Individual and Group Level Evidence (R21)

To improve health and reduce the burden of disease, scientific research needs to be implemented at the population level in addition to the biological and clinical levels. The purpose of this funding opportunity announcement (FOA) is to support multilevel, transdisciplinary population health interventions that target underlying social, economic, and environmental conditions in an effort to improve health outcomes.

Applications due October 16, 2017

  Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21) (Deadline: 10/16/17)

Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to provide support for the development of innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at:

  1. Testing new theories and conceptual frameworks;
  2. Developing and evaluating novel strategies to improve cancer-related health behaviors;
  3. Investigating multi-level and multi-behavioral approaches; and
  4. Utilizing innovative research designs, methodologies, and technologies.

The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve any aspect of the cancer continuum and any phase of the translational spectrum.

Applications due October 16, 2017

  Consortium Linking Oncology with Thrombosis (CLOT) (U01) (Deadline: 10/23/17)

Consortium Linking Oncology with Thrombosis (CLOT) (U01)

The purpose of this FOA is to establish a program which will provide support for the collaborative efforts of oncologists and coagulation/vascular experts to identify, further develop, and implement advances in thrombosis and hemostasis research into practice for cancer patients.

Applications due October 23, 2017

  KRAS Fellowship – Pancreatic Cancer Action Network | NCI, Frederick National Laboratory for Cancer Research (Deadline: 10/27/17)

KRAS Fellowship – Pancreatic Cancer Action Network | NCI, Frederick National Laboratory for Cancer Research

The KRAS Fellowship provides $100,000 in research funding over a two-year period. The grant term begins on July 1, 2017, and concludes on June 30, 2019. In addition to the research grant, Fellows are provided with $5,000 in travel support plus housing to visit FNLCR.

During the grant term, Fellows are given guest researcher status at FNLCR and are trained and granted access to onsite technology to support their funded research. They also receive support from the RAS Initiative team in planning experimental approaches for their funded project, mentorship from the RAS Initiative leadership and opportunities to participate in scientific lab meetings and workshops and to forge collaborations with other RAS researchers.

Fellows also attend the Pancreatic Cancer Action Network's Annual Scientific Meeting (scheduled for August 17-20, 2017, and dates to be determined in 2018 and 2019). This meeting brings together grant recipients and members of the organization’s Scientific and Medical Advisory Board for research feedback, knowledge exchange, mentorship and collaboration. Support for travel to the annual meeting is provided separate from the Fellowship grant.

Applications due October 27, 2017

National Institutes of Health (NIH)

Open AllClose All
  Time-Sensitive Obesity Policy and Program Evaluation (R01)

Time-Sensitive Obesity Policy and Program Evaluation (R01)

This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding.

All applications to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications in response to this time-sensitive FOA are not eligible for resubmission. It is intended that eligible applications selected for funding will be awarded within four months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.

Applications due on a continuous basis (once per month)

  Expanding Genome Integrity Assays to Population Studies (U01) (Deadline: LOI by 8/30/17; to NCI by 10/13/17)

Expanding Genome Integrity Assays to Population Studies (U01)

The funding opportunity announcement (FOA) will support development and pilot testing of assays, such as DNA repair capacity or mutation detection, that will facilitate the wider use of genome integrity investigation in epidemiological and population studies. NCI is particularly interested in studies that include data with cancer related phenotypes and tools that facilitate such investigation.

*Limited Submission

Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The NIH will not accept duplicate or highly overlapping applications under review at the same time. This means that the NIH will not accept:

  • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
  • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
  • An application that has substantial overlap with another application pending appeal of initial peer review (see NOT-OD-11-101).

Please submit LOI by August 30, 2017 so we can decipher if science is scientifically distinct.

Deadline for Application to NCI: October 13, 2017

Department of Defense (DOD)

Foundations & Organizations

Open AllClose All
  Educational Grants (Bayer AG; Bayer USA Foundation) (Deadlines: 8/8/17 for Oncology; 10/1/17 for Generic Education)

Educational Grants (Bayer AG; Bayer USA Foundation)

The goal of the contributions and educational grants initiatives is to promote the general prevention and treatment of disease and illness. Bayer strategically focuses its funding in support of research, education and patient support. As a commitment to improving patient care and providing valuable information to the medical and broader healthcare community, Bayer HealthCare will accept the following grant requests:

  1. Healthcare professional education
  2. Patient advocacy and Consumer education programs (e.g., disease-state education and awareness, screenings, camps, etc.)

Areas of Support:

  • Dermatology
  • Radiology
  • Hematology-Hemophilia
  • General Medicine (Pulmonology/Cardiology/Infectious Disease/Non-Cystic Fibrosis Bronchiectasis)
  • Neurology
  • Women's Health

Oncology:

  • Advanced Prostate Cancer
  • Colorectal Cancer
  • Gastrointestinal Stromal Tumor
  • Hepatocellular Carcinoma
  • Thyroid Cancer

Applications due August 8, 2017 (Oncology); October 1, 2017 (Generic Education)

  St Baldrick’s Foundation (SBF) (Deadline: 8/31/17)

St Baldrick’s Foundation (SBF)

These grants are not for a specific research project, but rather for resources to allow more research to be done. They support institutions with the potential for more participation in childhood cancer clinical trials, but which currently lack necessary resources (primarily support for Clinical Research Associates). Infrastructure grants are designed to provide an infusion of funds to enable an institution to acquire the personnel (i.e., a clinical research associate) or resources it needs to reach its potential in broader clinical trial participation. The applicant should indicate how ongoing personnel costs will be funded in future years.

Applications due August 31, 2017

  Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G. (Deadline: TBA)

Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G.

Graduate Training in Disparities Research (GTDR) Grants are intended to establish and/or to sustain a training program for graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups.

By providing funding to outstanding training programs, Komen seeks to ensure that a diverse pool of highly trained scientists will emerge as the next generation of leaders in the field of breast cancer research focused on disparities in breast cancer outcomes.

The research training program should be designed to meet the following goals:

  • Attract graduate students, specifically those from populations affected by disparities in breast cancer outcomes, into research careers.
     
  • Empower these students with the skills and knowledge necessary to effectively explore the causes of differential breast cancer outcomes and develop interventions to reduce and eliminate such disparities.

Deadline TBA

  Distinguished Scholars | Lustgarten Foundation

Distinguished Scholars | Lustgarten Foundation

The Distinguished Scholars program supports world-class scientists, who are at the top in their field, and are at the forefront of today's most exciting breakthroughs in pancreatic cancer research. Selected by The Lustgarten Foundation's Scientific Advisory Board (SAB), each grantee will receive $5 million in funding over the next five years, enabling these scientists to purse high-risk high-reward science, dedicate more of their time and focus to pancreatic cancer research, and accelerate a path to a cure.

The Distinguished Scholar Award is given on a discretionary basis and is not part of the annual grant program.

  Komen Southeast Wisconsin's Small Grant Program

Komen Southeast Wisconsin's Small Grant Program

Any non-profit organization in the Komen Southeast Wisconsin service area can apply for up to $5,000 for a small pilot or capacity-building breast health program grant. These grants are for organizations interested in beginning a new program or testing new ideas that will increase the innovative capacity and effectiveness of breast health programs that serve low income and uninsured women.

Small Grants are available in two categories:

  1. Education/Outreach Grants will support the development of breast cancer programs or projects.
     
  2. Capacity Building/Technical Assistance Grants will provide funding to increase the efficiency and effectiveness of an organization's ability to provide services by redesigning processes, implementing new practices, or developing collaborations or partnerships.

Applications due on a continuous basis throughout funding cycle

  Pediatric Low Grade Astrocytomas Foundation (PLGA)(Applications continuous)

Pediatric Low Grade Astrocytomas Foundation (PLGA)

The number one priority of A Kids' Brain Tumor Cure Foundation is to act as a catalyst for researchers world-wide to turn their attention to the area of pediatric low grade glioma brain tumor research and to award research grants for the most promising programs and studies. The hope is that this research will lead to a better understanding of the causes of PLGA as well as the discovery of more effective treatments and a cure for the most common forms of children's brain tumors.

Proposals related to basic and translational* projects that can advance understanding of the underlying biology of the development and treatment of PLGA tumors will be considered.

*NIH definition of translational research: the process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment or prevention of human disease.

Applications continuous

  SWOG Trial Support (STrS) – The Hope Foundation (Applications continuous)

SWOG Trial Support (STrS) – The Hope Foundation

SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. SWOG is a National Cancer Institute-supported network of more than 5,000 cancer researchers at more than 650 institutions in the U.S., Canada, and beyond. Additional educational and cancer research support is provided by SWOG's non-profit, philanthropic partner, The Hope Foundation.

STrS is a peer-reviewed program administered by The Hope Foundation in conjunction with SWOG. STrS is designed to support trial components that need supplemental funding during patient enrollment in a SWOG study. Qualifying components may include things that are outside of the SWOG-supported norm, such as atypical requests for tissue and/or data, or provision of materials to trial sites.

Applications continuous

Pancreatic Cancer Action Network

Institutional

Other

Open AllClose All
  Breast Cancer Alliance (BCA) (Deadline: 7/22/17)

Breast Cancer Alliance (BCA)

The mission of the Breast Cancer Alliance (BCA) is to improve survival rates and quality of life for those impacted by breast cancer through better prevention, early detection, treatment and cure. To promote these goals, the BCA invests in innovative research, breast surgery fellowships, regional education, dignified support and screening for the uninsured and underserved.

The BCA offers the Young Investigator Grant to encourage a commitment to breast cancer research. This grant is intended to help advance the careers of young researchers who do not yet have their own major grant support.

Applications due July 22, 2017

  Pragmatic Clinical Studies to Evaluate Patient-Centered Outcomes (Deadline: LOI's due 7/25/17; Applications due 10/25/17)

Pragmatic Clinical Studies to Evaluate Patient-Centered Outcomes

PCORI seeks to fund pragmatic clinical trials, large simple trials, or large-scale observational studies that compare two or more alternatives for addressing prevention, diagnosis, treatment, or management of a disease or symptom; improving healthcare-system-level approaches to managing care; communicating or disseminating research results to patients, caregivers, or clinicians; or eliminating health or healthcare disparities. Proposed studies must address critical clinical choices that patients, their caregivers, clinicians, or delivery systems face. They must involve broadly representative patient populations and be large enough to provide precise estimates of hypothesized effectiveness differences and to support evaluation of potential differences in treatment effectiveness in patient subgroups.

LOI’s due July 25, 2017; Applications due October 25, 2017

  Brian D. Novis Senior Research Award (Deadline: 8/1/17)

Brian D. Novis Senior Research Award

These awards go to researchers doing work in the field of multiple myeloma and related disorders including smoldering myeloma, MGUS (monoclonal gammopathy of undetermined significance) as well as immunoglobulin derived amyloidosis. These awards are targeted to established investigators with a track record in myeloma or related disorders, and are designed for projects which represent a different focus, direction, or area of research from those in which they are currently funded.

In most cases, these awards will be for pilot projects to obtain sufficient funding for larger applications from NIH or similar larger funding agencies.

Applications due August 1, 2017

  Radiation Science and Technology Award (Deadline: 8/1/17)

Radiation Science and Technology Award

Established in 1967, this award recognizes outstanding creative applications of radiation sciences and engineering principles. Qualification is based on meritorious scientific and engineering achievement that has important implications for radiation science and technology. The work may have been performed at any time in the past, but the findings must have been reported in peer reviewed scientific journals. In addition, the feasibility of industrial application(s) must have been established although the work need not be in widespread use at the time of the award. The nominee need not be an ANS member. Any ANS member can nominate a worthy candidate.

Nominations due August 1, 2017

  R. Robert and Sally Funderburg Research Award in Gastric Cancer (Deadline: 8/4/17)

R. Robert and Sally Funderburg Research Award in Gastric Cancer

This grant is awarded to an established investigator working on novel approaches in gastric cancer research, including the fields of gastric mucosal cell biology; regeneration and regulation of cell growth (not as they relate to peptic ulcer disease or repair); inflammation (including Helicobacter pylori) as precancerous lesions; genetics of gastric carcinoma; oncogenes in gastric epithelial malignancies; epidemiology of gastric cancer; etiology of gastric epithelial malignancies; or clinical research in the diagnosis or treatment of gastric carcinoma.

The overall objective of this award is to support an established investigator in the field of gastric biology whose research will enhance the fundamental understanding of gastric cancer pathobiology in order to ultimately prevent or develop a cure for the disease. Applications that do not denote a gastric biology focus and are not responsive to this announcement will not be submitted for review.

Applications due August 4, 2017

  Prostate Cancer Research Program (PCRP)- Physician Research Award (Deadline: 8/10/17)

Prostate Cancer Research Program (PCRP)- Physician Research Award

The Physician Research Award supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. The mentored physician is considered the Principal Investigator (PI) of the application. This award emphasizes equally the quality of the proposed research project and the career development of the PI, which should prepare physicians for careers in basic, population science, translational, or clinical prostate cancer research.

Applications due August 10, 2017

  SWOG/Hope Foundation Impact Award (Deadline: 9/1/17)

SWOG/Hope Foundation Impact Award

SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. SWOG is a National Cancer Institute-supported network of more than 4,000 cancer researchers at more than 500 institutions in the U.S., Canada, and beyond. Additional educational and cancer research support is provided by SWOG's non-profit, philanthropic partner, The Hope Foundation. Must be a SWOG member to qualify.

Applications due September 1, 2017

  Stand Up To Cancer (SU2C) Dream Team Translational Research Grant (Deadline: LOI by 9/5/17; Invited Full Proposal by 1/16/18)

Stand Up To Cancer (SU2C) Dream Team Translational Research Grant

The Stand Up To Cancer Dream Team Translational Research Grant will fund a translational cancer research project that will address critical problems in patient care, including prevention strategies for those at risk, and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, collaborative Dream Team of expert investigators.

The ideas may focus on particular organ sites, patient populations (such as pediatrics) or on innovative methods of treatment. Projects must be designed to accelerate the application of new preventive, diagnostic or therapeutic approaches to the clinic (i.e., lead to patient involvement within 2-3 years from the beginning of the grant). Proposals for Dream Team research projects must present plans indicating how the work will be translated into the clinic. The ideas should be based on perceived opportunities for success as well as high-priority areas with a critical need for rapid progress beyond current medical care.

LOI due September 5, 2017

Invited full proposals due January 16, 2018

  Adolescent/Young Adult Cooperative Group Correlative Studies Grant (Deadline) 9/6/17)

Adolescent/Young Adult Cooperative Group Correlative Studies Grant

The Lymphoma Research Foundation (LRF) seeks proposals for correlative clinical/translational studies in adolescent/ young adult (AYA) lymphomas. Applications to this initiative may focus on either biomarkers and the biology of AYA lymphomas, or clinical outcomes/survivorship and health services studies which specifically impact the AYA lymphoma population.

Applications due September 6, 2017

  Clinical Investigator Career Development Grant (Deadline: 9/6/17)

Clinical Investigator Career Development Grant

The goal of the program is to prepare physician investigators to design and administer clinical research studies in lymphoma and assume primary responsibilities for clinical research, protocol writing, Institutional Review Board (IRB) submission and publication. As such, a Career Development Plan is required as part of the Grant Application. The proposed research plan should also develop the necessary knowledge and clinical research skills relevant to the investigator's career goals. The Grant is designed to provide physician investigators with support to spend 35-50 percent of their time implementing clinical research studies in lymphoma.

**All projects must be focused on hypothesis-driven clinical research in lymphoma. The project should be developed by the Applicant and should include at least the framework of a research protocol**

Applications due September 6, 2017

  Mantle Cell Lymphoma Therapeutic Studies Grant (Deadline: 9/6/17)

Mantle Cell Lymphoma Therapeutic Studies Grant

The Lymphoma Research Foundation (LRF) seeks proposals for clinical/translational studies, including correlative studies, in mantle cell lymphoma (MCL). Applications to this initiative should relate to work in the clinical setting and/or involve primary MCL patient samples. Proposals which are adjunct to an existing research project in MCL are strongly encouraged.

Applications due September 6, 2017

  Prostate Cancer Research Program (PCRP) - Cancer Clinical Consortium Award (CCA) (Deadline: 9/7/17)

Prostate Cancer Research Program (PCRP) - Cancer Clinical Consortium Award (CCA)

The mission of the FY17 PCRP is to find and fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of men experiencing the impact of the disease. Specifically, the PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; multidisciplinary, synergistic research; translational studies to support the fluid transfer of knowledge between bedside and bench; research on patient survivorship and quality of life; the next generation of prostate cancer investigators through mentored research; and research on disparities in the incidence and mortality of prostate cancer.

Applications due September 7, 2017

  Urology Care Foundation Research Scholars Awards (Deadline: 9/13/17)

Urology Care Foundation Research Scholars Awards

The Urology Care Foundation, the official foundation of the American Urological Association (AUA),works to ensure the future of urologic health by supporting and improving the prevention, detection, and treatment of urologic diseases through research and education. The Urology Care Foundation has recognized a major need to encourage bright, young physician-scientists and researchers to dedicate their careers to improving patients' lives through better understanding of the development and management of urologic diseases and conditions.

Eligibility

Track 1:

  • Urologists in accredited clinical fellowships (eligible until the end of clinical fellowship)
  • Post-doctoral fellows no more than five years beyond completion of the PhD

Track 2:

  • Early-career MD (urologist) or PhD investigators within the first five years after beginning their faculty positions.

Applications due September 13, 2017

  Hope Funds for Cancer Research-Postdoctoral Fellowship (Pre-Applications Deadline: 9/15/17; Full application Deadline: 1/14/18)

Hope Funds for Cancer Research-Postdoctoral Fellowship

The Hope Funds for Cancer Research is offering fellowships to postdoctoral scientists who propose to work on highly innovative research projects that challenge the traditional paradigms of understanding the causes, mechanisms, progression, disease markers or risk factors of the most difficult-to-treat cancers, including pancreatic, lung, liver, sarcomas, esophageal, brain, gastric, bone and ovarian cancers; and rare leukemias, lymphomas and MDS.

Pre-Applications due September 15, 2017; Application due January 14, 2018

  CONquer canCER Now Award (Deadlines: LOI by 9/7/17; Full Proposal by 12/7/17)

CONquer canCER Now Award

By specifically targeting promising early-career scientists and providing critically needed "seed" money for innovative projects, Concern Foundation supports development of the next generation of cancer researchers and thus promotes progress in understanding cancer biology and improved approaches to cancer.

**Proposals must be hypothesis-driven and centered on cancer genetics, cancer biology, or cancer immunology**

Concern will not fund clinical trials, cancer epidemiology, or behavioral studies.

LOI due September 7, 2017

Full Proposal due December 7, 2017

  Prostate Cancer Research Program (PCRP) - Cancer Clinical Consortium Award (CCA) (Deadline: 9/7/17)

Prostate Cancer Research Program (PCRP) - Cancer Clinical Consortium Award (CCA)

The mission of the FY17 PCRP is to find and fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of men experiencing the impact of the disease. Specifically, the PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; multidisciplinary, synergistic research; translational studies to support the fluid transfer of knowledge between bedside and bench; research on patient survivorship and quality of life; the next generation of prostate cancer investigators through mentored research; and research on disparities in the incidence and mortality of prostate cancer.

Applications due September 7, 2017

  Prostate Cancer Research Program (PCRP)- Pathology Resource Network Award (Deadline: 9/7/17)

Prostate Cancer Research Program (PCRP)- Pathology Resource Network Award

The FY17 PCRP PCPRN Award is intended to provide infrastructure support for the development and maintenance of a prostate cancer biorepository through a collaborative network across multiple institutions that will facilitate the collection, processing, annotation, storage, and distribution of high-quality human prostate cancer biospecimens. A major focus of the Network must be placed on the acquisition and distribution of specimens in limited supply, such as:

  • Castration-resistant disease, metastatic disease, primary untreated "de novo" metastatic disease as defined by STAMPEDE or high-risk disease defined by CHAARTED, tumors of the aggressive variant phenotype
  • Disproportionately affected populations, defined by ethnicity or health service access (safety net, rural, settings)
  • Active surveillance populations
  • Longitudinal/sequential specimens

The Network must also collect, store, and manage data derived from the distributed biospecimens, including images of the hematoxylin and eosin (H&E)-stained samples.

Applications due September 7, 2017

  Gilead Sciences Research Scholars Program in Hematology/Oncology (Deadline: 9/8/17)

Gilead Sciences Research Scholars Program in Hematology/Oncology

The mission of the program is to support innovative scientific research that will advance knowledge in the field of hematology/oncology, with a focus on hematologic malignancies, and provide support for research career development. Gilead Sciences, Inc. hopes that the research supported by these awards will enhance understanding in hematology/oncology.

The program is designed to support innovative translational research projects in hematology/oncology, with a focus on hematologic malignancies, that can be either based around a clinical trial with strong correlative science or laboratory investigation.

Applications due September 8, 2017

  Prostate Cancer Research Program (PCRP)- Health Disparity Research Award (Deadline: 9/28/17)

Prostate Cancer Research Program (PCRP)- Health Disparity Research Award

The Health Disparity Research Award supports new ideas based on innovative concepts or methodologies for health disparity research with the potential to make an important contribution toward eliminating death from prostate cancer and enhancing the well-being of men impacted by the disease. Studies proposed for this award mechanism are expected to improve the understanding of and/or address factors that contribute to differences in the disease experience across populations, ultimately contributing to eliminating disparities in prostate cancer incidence, morbidity, mortality, and survivorship.

Applicants for this award must explicitly state how the proposed research is related to an area of prostate cancer health disparity. The PCRP is interested in research that addresses all different aspects that contribute to health disparity in prostate cancer, including social, cultural, and/or biological contributors. Because of the emphasis on innovation, the inclusion of preliminary data relevant to prostate cancer and the proposed project is encouraged but not required.

Any preliminary, unpublished data provided should be from the Principal Investigator (PI) or a member(s) of the research team.

Applications due September 28, 2017

  Administrative Supplements for Research on Dietary Supplements (Admin Supp) (Deadline: 10/15/17)

Administrative Supplements for Research on Dietary Supplements (Admin Supp)

This Funding Opportunity Announcement (FOA) announces the availability of administrative supplements to support research in which the supplemental funding would investigate the role of dietary supplements and/or their ingredients in health maintenance and disease prevention.

Parent awards need not be focused on dietary supplements; this FOA may provide support to include dietary supplements within the scope of relevant research projects. Research interests of ODS are not limited to specific health conditions, organ systems or population groups. ODS supports all types of research, including pre-clinical, clinical, behavioral, and epidemiological. Additionally, ODS supports research and training programs that build future research capacity for studying the role of dietary supplements in health and disease prevention.

Primary consideration for support will be given to applications that stimulate dietary supplement research where it is lacking or lagging, clarify gaps, opportunities and balance between benefits and risks where data are in conflict, target special population groups where additional science on dietary supplements is needed, and focus on the use of dietary supplements in improving or maintaining health and reducing the risk of chronic disease.

This FOA will not support new clinical trials.

Applications due October 15, 2017

  Understanding, Preventing, and Managing Immunotherapy-related Adverse Events (irAEs) Associated with Checkpoint Inhibition for Melanoma and Other Cancers (Deadline: 10/16/17)

Understanding, Preventing, and Managing Immunotherapy-related Adverse Events (irAEs) Associated with Checkpoint Inhibition for Melanoma and Other Cancers

To facilitate research focused on prevention, risk, early detection, and management of short- and long-term immune-related adverse events (irAEs) associated with FDA-approved or late-stage development checkpoint cancer immunotherapies for melanoma and other cancers.

Applications due October 16, 2017

  Symptom Management for Patients with Advanced Illness – (Cycle 2 2017) (Deadline: 10/25/17)

Symptom Management for Patients with Advanced Illness – (Cycle 2 2017)

The Patient-Centered Outcomes Research Institute (PCORI) is launching this research initiative to generate needed scientific evidence to aid patients, caregivers, and providers in decision making about the clinical options for symptom management in advanced illness. PCORI seeks to fund multiple high-quality clinical studies comparing evidence-based pharmacological and non-pharmacological treatments for the range of symptoms experienced by patients with advanced illness. This PCORI Funding Announcement (PFA) focuses specifically on the following symptoms:

  • Pain
  • Fatigue
  • Dyspnea
  • Insomnia
  • Anorexia/cachexia
  • Nausea/vomiting
  • Depression and/or anxiety

This PFA is targeted toward advanced illnesses such as (but not limited to) advanced heart failure, advanced cancer, chronic obstructive pulmonary disease, end-stage liver and kidney disease, or neurodegenerative diseases.

Applications due October 25, 2017

  Translational Research Program (Deadline: 11/15/17)

Translational Research Program

The Translational Research Program puts you on the bench-to-bedside fast track when it comes to finding better treatment and cures for leukemia, lymphoma and myeloma. The Leukemia & Lymphoma Society funds new and innovative research that shows high promise for translating basic biomedical knowledge to clinical application.

Applications due November 15, 2017

  Desmoid Tumor Research Foundation (Deadline: 1/12/18)

Desmoid Tumor Research Foundation

The Desmoid Tumor Research Foundation, Inc. (“DTRF”) funds research that will advance the current scientific knowledge about desmoid tumors, moving toward the development of new treatment options and bringing us closer to our ultimate goal of a cure. DTRF is the only foundation in the world dedicated to facilitating and funding research for a cure for desmoid tumors.

We fund research that uses cutting-edge science and creative clinical applications, in addition to novel approaches addressing potential leads based on prior research. Research proposals with additional sources of funding support are particularly desirable. Researchers must be willing to collaborate with other scientists and institutions with similar interests. Grantees must agree to participate as reviewers in DTRF’s future grant review cycle, as well as to exert best efforts to attend the annual fall International DTRF Desmoid Tumor Research Workshop

Applications due January 12, 2018

  Fanconi Anemia Research Fund (Deadline: 2/2/18)

Fanconi Anemia Research Fund

The Fund seeks to improve the lives of individuals with Fanconi anemia through research that focuses on the rapid discovery and development of therapies or strategies that treat, control or cure Fanconi anemia. It has a particular interest in funding interdisciplinary, translational research efforts that effectively address one or more of the following priorities:

  • To understand how alteration of the Fanconi anemia genes and their products lead to the clinical manifestations of Fanconi anemia.
  • To determine the causes of bone marrow failure, myelodysplasia and leukemia in individuals with Fanconi anemia, and to develop strategies to prevent, treat and cure these disorders.
  • To define the pathogenesis of cancers that affect persons with Fanconi anemia, and to develop strategies for early detection, prevention, treatment and cure.
  • To identify practical and proactive management strategies that families and persons with Fanconi anemia can use to develop and maintain a high quality of life.
  • To support the creation of shared resources, databases and technologies for the international Fanconi anemia research community.

Applications due February 02, 2018

  Adenoid Cystic Carcinoma Research Foundation (Deadline: Continuous)

Adenoid Cystic Carcinoma Research Foundation

Adenoid Cystic Carcinoma (ACC) is a rare malignancy of secretory glands, typically originating in the salivary glands though it does appear in other primary sites, including the palate, nasopharynx, tongue base, larynx, trachea, lacrimal gland, breast and vulva. There are approximately 1,200 new cases of ACC diagnosed each year in the United States, about 60% of which involve women. This cancer has a slow, and sometimes relentless, progression characterized by frequent recurrences and metastases to sites such as the lungs, liver and bones.

Deadline continuous

  Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) (Deadline: Continuous)

Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)

Medical Educational Grants are independent educational activities that utilize effective educational methods to address unmet medical needs that leads to improved patient outcomes. A Boehringer Ingelheim Pharmaceuticals, Inc. medical educational grant is designed to provide support for accredited educational programs for health care providers and non-accredited educational programs directed toward the patient and the local health care community.

The Medical Education Grants Department consists of education professionals who facilitate lifelong learning for clinicians and patients through support of independent education. BIPI's Medical Education and Research Grants department is committed to supporting innovative, high quality, independent medical education and research for healthcare professionals and patients that resolves unmet medical needs, fosters clinical excellence, and measurably improves health outcomes in areas of strategic focus to BIPI.

The sponsor considers funding of activities in many therapeutic areas including:

  • Therapeutic Areas Cardiovascular Disease – Stroke Prevention in Atrial Fibrillation
  • Cardiovascular Disease – Venous Thromboembolism (VTE)
  • Immunology – General Immunology
  • Oncology – Acute Myeloid Leukemia (AML)
  • Oncology – Lung Cancer
  • Respiratory Disease – Chronic Obstructive Pulmonary Disease (COPD)
  • Respiratory Disease – Interstitial Lung Disease (ILD)

Funding may be limited or exhausted in some therapeutic areas. BIPI will review and consider support of those requests in the areas above. To that end, educational objectives have been identified that are derived from evidence based science and are intended to close gaps in research, knowledge, or behaviors that represent barriers in care and patient outcomes.

Deadline continuous

  UICC Technical Fellowships (UICC-TF) [previously Global Education and Training Initiative (GETI): International Cancer Technology Transfer Fellowships (ICRETT)] (Deadline Continuous)

UICC Technical Fellowships (UICC-TF) [previously Global Education and Training Initiative (GETI): International Cancer Technology Transfer Fellowships (ICRETT)]

The aim of the UICC ICRETT fellowships is to facilitate rapid international transfer of cancer research and clinical technology, exchange knowledge and enhance skills in basic, clinical, behavioural and epidemiological areas of cancer research cancer control and prevention and to acquire appropriate clinical management, diagnostic and therapeutic expertise for effective application and use in the home organization upon return.

  • Research plan
    • Cancer prevention and control (including tobacco control)
    • Basic, applied and clinical cancer research Epidemiology,
    • Cancer registration, public education and behavioral sciences
  • Clinical training
    • Surgery, radio and chemotherapy, medical oncology, multidisciplinary cancer care
    • Clinical trials
    • Detection and diagnosis Prevention-oriented projects are especially encouraged

Deadline Continuous

  Sanofi-Aventis U.S. Inc. Education Grants (Deadline continuous)

Sanofi-Aventis U.S. Inc. Education Grants

Sanofi US is committed to funding high quality educational activities and materials in the therapeutic areas of interest to the company that have the potential to improve patient care and health outcomes.

The purpose of an educational grant is to support an activity that encourages an educational interchange with respect to available scientific and medical information. Educational activities may or may not be accredited.

Educational Grants fund educational activities and materials designed to improve the knowledge, competence (skill) and/or performance of healthcare professionals, patients, and/or consumers for improved patient care and outcomes.

Grants may be given for live educational activities, as well as educational publications and other types of enduring materials (e.g. interactive web, CD rom, audio tapes, etc.) provided that the activities or materials are advertised and open to a broad audience beyond members of the requesting institution. Fellowships or career development awards may be considered in limited circumstances.

Applicant must select one of the following Therapeutic Areas:

  • Cardiovascular
  • Diabetes
  • Genetic Diseases
  • Immunology
  • Multiple Sclerosis
  • Oncology
  • Orthopedics
  • Renal
  • Thyroid Cancer
  • Transplantation

Deadline continuous

Follow:

 

Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53226
(414) 955-8296
Directions & Maps
© 2017

 

 

Page Updated 07/19/2017
Top